JP2014531465A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531465A5
JP2014531465A5 JP2014533880A JP2014533880A JP2014531465A5 JP 2014531465 A5 JP2014531465 A5 JP 2014531465A5 JP 2014533880 A JP2014533880 A JP 2014533880A JP 2014533880 A JP2014533880 A JP 2014533880A JP 2014531465 A5 JP2014531465 A5 JP 2014531465A5
Authority
JP
Japan
Prior art keywords
pyridin
indazol
pyrimidin
methoxy
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014533880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531465A (ja
JP6140170B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/069562 external-priority patent/WO2013050438A1/en
Publication of JP2014531465A publication Critical patent/JP2014531465A/ja
Publication of JP2014531465A5 publication Critical patent/JP2014531465A5/ja
Application granted granted Critical
Publication of JP6140170B2 publication Critical patent/JP6140170B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014533880A 2011-10-06 2012-10-04 過増殖性疾患の処置におけるbub1キナーゼ阻害剤として使用するための置換ベンジルインダゾール類 Expired - Fee Related JP6140170B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184061.7 2011-10-06
EP11184061 2011-10-06
PCT/EP2012/069562 WO2013050438A1 (en) 2011-10-06 2012-10-04 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Publications (3)

Publication Number Publication Date
JP2014531465A JP2014531465A (ja) 2014-11-27
JP2014531465A5 true JP2014531465A5 (OSRAM) 2016-01-14
JP6140170B2 JP6140170B2 (ja) 2017-05-31

Family

ID=46968229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533880A Expired - Fee Related JP6140170B2 (ja) 2011-10-06 2012-10-04 過増殖性疾患の処置におけるbub1キナーゼ阻害剤として使用するための置換ベンジルインダゾール類

Country Status (38)

Country Link
US (3) US20140249133A1 (OSRAM)
EP (1) EP2763982B1 (OSRAM)
JP (1) JP6140170B2 (OSRAM)
KR (1) KR102007056B1 (OSRAM)
CN (1) CN103974948B (OSRAM)
AP (1) AP3847A (OSRAM)
AR (1) AR088449A1 (OSRAM)
AU (1) AU2012320582B2 (OSRAM)
BR (1) BR112014008045A2 (OSRAM)
CA (1) CA2851037A1 (OSRAM)
CO (1) CO6930363A2 (OSRAM)
CR (1) CR20140161A (OSRAM)
CU (1) CU20140043A7 (OSRAM)
CY (1) CY1120318T1 (OSRAM)
DK (1) DK2763982T3 (OSRAM)
DO (1) DOP2014000062A (OSRAM)
EA (1) EA201400412A1 (OSRAM)
EC (1) ECSP14013284A (OSRAM)
ES (1) ES2665036T3 (OSRAM)
GT (1) GT201400063A (OSRAM)
HR (1) HRP20180546T1 (OSRAM)
HU (1) HUE037154T2 (OSRAM)
IL (1) IL231591A (OSRAM)
LT (1) LT2763982T (OSRAM)
MX (1) MX361279B (OSRAM)
NO (1) NO2763982T3 (OSRAM)
PE (1) PE20141203A1 (OSRAM)
PH (1) PH12014500758A1 (OSRAM)
PL (1) PL2763982T3 (OSRAM)
PT (1) PT2763982T (OSRAM)
RS (1) RS57099B1 (OSRAM)
SG (1) SG11201400616YA (OSRAM)
SI (1) SI2763982T1 (OSRAM)
TN (1) TN2014000138A1 (OSRAM)
TW (1) TWI588141B (OSRAM)
UA (1) UA111754C2 (OSRAM)
UY (1) UY34374A (OSRAM)
WO (1) WO2013050438A1 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EP2794596B1 (en) 2011-12-21 2017-05-31 Bayer Intellectual Property GmbH Substituted benzylpyrazoles
CN104411701B (zh) * 2012-05-11 2017-01-18 拜耳医药股份有限公司 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑
EP2976334A1 (en) * 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
CA2907594A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
CN105452236A (zh) * 2013-06-21 2016-03-30 拜耳制药股份公司 取代的苄基吡唑
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
JP2016522232A (ja) * 2013-06-21 2016-07-28 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換されたピラゾール類
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
HK1222852A1 (zh) * 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 二氨基杂芳基取代的吡唑
CA2928998A1 (en) * 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
TW201613886A (en) * 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PE20170697A1 (es) * 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
US20170275269A1 (en) * 2014-09-19 2017-09-28 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
EP3194378A1 (en) * 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles
WO2016042080A1 (en) * 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
SG11201705908VA (en) 2015-01-28 2017-08-30 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
HRP20200064T1 (hr) * 2015-06-09 2020-04-03 Abbvie Inc. Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti
EP3310775B1 (en) * 2015-06-17 2020-04-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
JP2019504826A (ja) * 2015-12-16 2019-02-21 バイエル ファーマ アクチエンゲゼルシャフト ヘテロ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
KR102048050B1 (ko) * 2019-08-29 2020-01-22 대한민국 Adb-푸비나카의 대사체 합성 방법
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024254266A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
JP4351298B2 (ja) 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE60223720T2 (de) 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
US8748601B2 (en) 2003-04-11 2014-06-10 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
WO2007065010A2 (en) * 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8796253B2 (en) 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
JP5580332B2 (ja) 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
WO2011049987A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
UY33476A (es) 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EP2794596B1 (en) 2011-12-21 2017-05-31 Bayer Intellectual Property GmbH Substituted benzylpyrazoles
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
CN104411701B (zh) 2012-05-11 2017-01-18 拜耳医药股份有限公司 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
CA2907594A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
EP2976334A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
JP2016522232A (ja) 2013-06-21 2016-07-28 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換されたピラゾール類
CN105452236A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 取代的苄基吡唑
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
HK1222852A1 (zh) 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 二氨基杂芳基取代的吡唑
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
PE20170697A1 (es) 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
EP3194378A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles
WO2016042080A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
US20170275269A1 (en) 2014-09-19 2017-09-28 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Similar Documents

Publication Publication Date Title
JP2014531465A5 (OSRAM)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
US9670208B2 (en) Serine/threonine kinase inhibitors
US8901147B2 (en) Bi-heteroaryl compounds as Vps34 inhibitors
JP2017500364A5 (OSRAM)
JP6500010B2 (ja) 新規ピリジン誘導体
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
RU2014139601A (ru) Ингибиторы серин/треониновых киназ
CA2531619A1 (en) Biaryl piperazinyl-pyridine analogues
JP2018512381A5 (OSRAM)
TW200536851A (en) Compounds and methods of use
JP2014528446A5 (OSRAM)
JP2016514717A5 (OSRAM)
US20120041024A1 (en) Quinolyl amines as kinase inhibitors
JP2016523976A5 (OSRAM)
JP2016530299A5 (OSRAM)
JP2014518214A5 (OSRAM)
JP2016522231A5 (OSRAM)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2011519891A5 (OSRAM)
JP2018508553A5 (OSRAM)
RU2014132044A (ru) Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
JP2019530708A5 (OSRAM)